$CON

S&P Global Ratings upgraded Concentra Group Holdings (NYSE:CON) to BB from BB-, citing lower leverage and strong performance. The company's adjusted leverage fell below 3.5x in Q2, with projections improving to 3x by fiscal 2027. Concentra generated $250M in annual free operating cash flow and increased EBITDA by over $100M since fiscal 2024, driven by growth and cost controls. S&P maintained a stable outlook but noted potential downgrade risks.

Concentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Stock Repurchase Agreement On August 21, 2026, Concentra Group Holdings Parent, Inc. (the “Company”) entered into a stock repurchase agreement (the “Stock Repurchase Agreement”) with Robert A. Ortenzio, chairman of the Company

ORTENZIO ROBERT A sold (to issuer) 230,000 indirectly-held shares of Concentra Group Holdings Parent, Inc. (CON) at an average of $34.78 ($34.65–$35.65, $8.00M total) across 4 trades on 2026-08-21.

ORTENZIO ROBERT A sold (to issuer) 770,000 shares of Concentra Group Holdings Parent, Inc. (CON) at $34.65 ($26.68M total) on 2026-08-21.

Biotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.

Concentra Group Holdings Parent (CON) reported Q2 2026 revenue of $606 million (+10% YoY) and adjusted EBITDA of $140.9 million (+22.5%), with adjusted EPS of $0.52. Management raised full-year guidance: revenue to $2.325B-$2.375B and adjusted EBITDA to $485M-$495M. Net leverage fell to 2.99x. A CEO transition to Matt DiCanio takes effect Nov. 1, 2026.

Concentra Group Holdings Parent (CON) shares rose about 11.5% to around $34 after its Q2 results. Revenue was $606.0m and adjusted EBITDA was $140.9m, implying a 23.3% margin versus about 20.9% a year earlier. Adjusted EPS was $0.52 and free cash flow was $121.0m, nearly double last year.

Concentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE FOR IMMEDIATE RELEASE Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance Matt DiCanio to become president and CEO and Keith Newton to transition to executive chairman, effective Nov. 1, 2026

ORTENZIO ROBERT A sold 130,000 indirectly-held shares of Concentra Group Holdings Parent, Inc. (CON) at $31.84 ($4.14M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Concentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 consultingagreementdated.htm EX-10.1 consultingagreementdated 1 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”), dated as of July 6, 2026, is made and entered into by and between John R. Anderson, D.O. (“Consultant”) and Concentra Health Services, Inc. (“Co